Vol 68, No 3 (2017)
Original paper
Published online: 2017-02-23

open access

Page views 1636
Article views/downloads 1439
Get Citation

Connect on Social Media

Connect on Social Media

Parathyroid hormone serum concentration in Central European patients with non-ischaemic heart failure as a potential marker of disease severity and poor prognosis

Grzegorz Marcin Kubiak1, Agnieszka Kolaszko1, Ewa Nowalany-Kozielska1
Pubmed: 28230891
Endokrynol Pol 2017;68(3):299-305.

Abstract

Introduction: Parathyroid hormone (PTH) might be considered as a potential marker of disease severity and worse prognosis in heart failure (HF) patients. The aim of the study was to assess PTH, vitamin D, phosphorus (P), and total calcium (Ca2+) serum concentrations in Central European patients suffering from HF of non-ischaemic origin compared to non-HF volunteers.To evaluate potential correlations among the enumerated parameters, established markers of worse prognosis and declared sun exposure.

Material and methods: Serum intact-PTH, 25-OH vitamin D, P, and total Ca2+ concentrations were assessed in a group of HF patients and non-HF volunteers. Patients described their daily profile of sun exposure during the previous eight weeks as “above” or “below” seven hours a week.

Results: The mean PTH concentrations in the non-ischaemic HF group and control group were 79.5 pg/mL and 59.6 pg/mL, respectively (P = 0.009). Non-HF volunteers declaring higher sun exposure time had higher serum concentrations of vitamin D compared to those with lower sun exposure time (30.3 vs. 23.8 ng/mL, P < 0.05), unlike the HF patients (24.1 ng/mL vs. 23.2 ng/mL, P = ns). Multiple regression analysis revealed the relationship between age, NT-proBNP (N-terminal pro-brain natriuretic peptide), P, and PTH as a dependent variable.

Conclusions: PTH is significantly elevated in non-ischaemic HF patients compared to non-HF volunteers and correlates with established factors of worse prognosis, including age, estimated glomerular filtration rate (eGFR), aspartate aminotransferase (AST), serum concentrations of creatinine, and NT-proBNP. Declared sun exposure did not affect the serum concentration of vitamin D in the HF group, in contrast to the control group.

References

  1. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal. 2012; 33: 1787-1847.
  2. Juppner H, Brown EM, Kronenberg HM. Parathyroid hormone. In: Favus M, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism, 4th Ed.Juppner H, Brown EM, Kronenberg HM. ed. Philadelphia: Lippincott Williams & Wilkins 1999: 80–87.
  3. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004; 80(6 Suppl): 1689S–96S.
  4. Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011; 22(2): 216–224.
  5. Hagström E, Ingelsson E, Sundström J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010; 12(11): 1186–1192.
  6. Zia AA, Komolafe BO, Moten M, et al. Supplemental vitamin D and calcium in the management of African Americans with heart failure having hypovitaminosis D. Am J Med Sci. 2011; 341(2): 113–118.
  7. Gotsman I, Shauer A, Zwas DR, et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail. 2012; 14(4): 357–366.
  8. Altay H, Colkesen Y. Parathyroid hormone and heart failure: novel biomarker strategy. Endocr Metab Immune Disord Drug Targets. 2013; 13(1): 100–104.
  9. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005; 111(7): 871–878.
  10. Loncar G, Bozic B, Dimkovic S, et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest. 2011; 34(3): e78–e85.
  11. Saleh FN, Schirmer H, Sundsfjord J, et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J. 2003; 24(22): 2054–2060.
  12. Chopra S, Cherian D, Jacob JJ. The thyroid hormone, parathyroid hormone and vitamin D associated hypertension. Indian J Endocrinol Metab. 2011; 15 Suppl 4: S354–S360.
  13. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998; 37(1): 34–41.
  14. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010; 31(13): 1591–1598.
  15. Khouzam RN, Dishmon DA, Farah V, et al. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci. 2006; 331(1): 30–34.
  16. Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011; 13(6): 626–632.
  17. Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009; 119(21): 2765–2771.
  18. Folsom AR, Alonso A, Misialek JR, et al. Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2014; 168(3): 296–302.
  19. di Giuseppe R, Buijsse B, Hirche F, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab. 2014; 99(3): 947–955.
  20. Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009; 95(5): 395–398.
  21. Gruson D, Lepoutre T, Ahn SA, et al. Increased circulating concentrations of bioactive PTH 1-84 in patients with heart failure. J Endocrinol Invest. 2012; 35(11): 987–991.
  22. Altay H, Zorlu A, Binici S, et al. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol. 2012; 109(2): 252–256.
  23. Sugimoto T, Dohi K, Onishi K, et al. Prognostic value of serum parathyroid hormone level in acute decompensated heart failure. Circ J. 2014; 78(11): 2704–2710.
  24. Tastan I, Schreckenberg R, Mufti S, et al. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res. 2009; 82(1): 77–83.
  25. Polat V, Bozcali E, Uygun T, et al. Low vitamin D status associated with dilated cardiomyopathy. Int J Clin Exp Med. 2015; 8(1): 1356–1362.
  26. www.solargis.info